SecBot SecBot
Biotech Drug Report Generated Nov 9, 2026

EXONDYS 51

SRPT·Sarepta Therapeutics, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed in the U.S. since September 2016.
Why 4/10
EXONDYS 51 is already approved and commercialized with no pending regulatory decision or pivotal readout for the drug itself. The next hard catalyst is the January 21, 2027 PDUFA date for Dyne Therapeutics' competing exon 51 drug z-rostudirsen, which is a competitive event rather than a catalyst for EXONDYS 51. Per the rubric, an approved drug with no upcoming binary catalyst scores 3-5; EXONDYS 51 is one of several products in Sarepta's portfolio, so it scores a 4.
Actionable Insight NEUTRAL

The next major catalyst for EXONDYS 51 is not a regulatory decision on the drug itself (already approved), but the January 21, 2027 PDUFA date for Dyne Therapeutics' competing exon 51 DMD drug z-rostudirsen. An approval would introduce direct competition to EXONDYS 51's core market. Separately, watch for Sarepta's quarterly revenue trends for the exon-skipping franchise and any updates on confirmatory trial data that could convert EXONDYS 51 from accelerated to traditional approval.

Price Chart

Loading chart...

Executive Summary

EXONDYS 51 (eteplirsen) is Sarepta Therapeutics' first-in-class antisense oligonucleotide for Duchenne muscular dystrophy (DMD) patients with exon 51 skipping-amenable mutations, approved by the FDA under accelerated approval in September 2016. It is a marketed, revenue-generating product and part of Sarepta's broader exon-skipping franchise (alongside AMONDYS 45 and VYONDYS 53). The drug faces a looming competitive threat: Dyne Therapeutics' z-rostudirsen, targeting the same exon 51 population, has a PDUFA target action date of January 21, 2027 under priority review. Sarepta reported Q3 2026 total revenue of $381.35 million and narrowed its 2026 product revenue guidance to $1.25-$1.3 billion, citing continued strength in its exon-skipping franchise. With no pending regulatory catalyst for EXONDYS 51 itself, the stock's next major binary event is the competitive PDUFA decision in early 2027.

How It Works

EXONDYS 51 is an antisense oligonucleotide, a short synthetic piece of genetic material designed to bind to a specific section of the dystrophin gene (exon 51). In Duchenne muscular dystrophy patients whose genetic mutation makes them candidates for exon 51 skipping, the drug effectively "hides" that exon during protein production, allowing the cell to skip over the faulty section and produce a shortened but still functional version of the dystrophin protein. This protein is essential for muscle cell integrity, and its absence causes the progressive muscle degeneration seen in DMD.

Trial Status

EXONDYS 51 was granted accelerated FDA approval in September 2016 for DMD patients with exon 51 skipping-amenable mutations, based on dystrophin production as a surrogate endpoint. Confirmatory post-marketing trials are ongoing to verify clinical benefit. The drug is commercially marketed in the U.S. and generated revenue as part of Sarepta's exon-skipping franchise, which the company cited as showing continued strength in its Q3 2026 earnings report.

The Two-Sided Case

▲ Bull Case3
EXONDYS 51 was the first FDA-approved drug for Duchenne muscular dystrophy and remains the only approved therapy for the ~13% of DMD patients amenable to exon 51 skipping, giving it a first-mover advantage and established commercial infrastructure.
Sarepta's Q3 2026 earnings highlighted continued strength in its exon-skipping franchise, and the company raised the low end of its 2026 product revenue guidance to $1.25-$1.3 billion, suggesting stable demand for EXONDYS 51 and its sister drugs.
Multiple institutional investors added or doubled their SRPT positions in Q2 and Q3 2026, including BlackRock, State Street, Goldman Sachs, and Vanguard, signaling confidence in the franchise's value.
▼ Bear Case4
Dyne Therapeutics' z-rostudirsen, targeting the same exon 51 DMD population, received FDA priority review with a PDUFA date of January 21, 2027. Citi noted z-rostudirsen could differentiate on higher efficacy and less frequent dosing, posing a direct competitive threat to EXONDYS 51's market share.
EXONDYS 51 was approved under accelerated approval based on a surrogate endpoint (dystrophin production), and confirmatory data have faced scrutiny. The drug has not been granted traditional FDA approval, leaving regulatory risk if confirmatory trials fail to demonstrate clinical benefit.
Analyst consensus on SRPT is mixed (12 buy/strong buy, 13 hold, 6 sell/strong sell) with a mean price target of $21.64, implying only ~21% upside from the $17.82 close. HC Wainwright reiterated a Sell rating with a $5 target in October 2026.
Several prominent institutional holders exited or severely trimmed SRPT positions in Q2 2026, including RA Capital Management (exit), Citadel Advisors (exit), and Canada Pension Plan Investment Board (94% trim), signaling concern about the competitive landscape.

Upcoming Catalysts

  • January 21, 2027: PDUFA target action date for Dyne Therapeutics' competing exon 51 DMD drug z-rostudirsen (priority review). An approval would introduce direct competition to EXONDYS 51.
  • Ongoing: Confirmatory post-marketing trial data for EXONDYS 51 that could support conversion from accelerated to traditional FDA approval.
  • Quarterly: Sarepta's exon-skipping franchise revenue trends in upcoming earnings reports.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Sarepta Therapeutics, Inc. 8-K SRPT ·Originating report

Sources · 7

Hover a chip for the title
1 raps.org2 biospace.com3 msn.com4 markets.financialcontent.com5 sec.gov6 marketscreener.com7 empr.com